Neuroendocrine cell hyperplasia of infancy (NEHI) is a rare interstitial lung disease of childhood that typically presents in the first year of life.
Neuroendocrine cell hyperplasia of infancy was previously reported as persistent tachypnea of infancy until the disease was found to be associated with an increased number of neuroendocrine cells on histopathology of lung biopsies.
NEHI typically occurs in the first year of life. Its current prevalence and incidence are not known but may be underreported as it is commonly misdiagnosed with other types of lung diseases. Etiology is unknown, but genetic factors are likely involved.
Infants typically present in respiratory distress with tachypnea, chest wall retractions, hypoxia, crepitations on auscultation of the chest, and failure to thrive.
The gold standard for diagnosis of neuroendocrine cell hyperplasia of infancy is demonstrating an increase in neuroendocrine cells with an otherwise normal lung architecture on tissue diagnosis. Standard staining will demonstrate essentially normal lung histology but shows an increase in Bombesin-positive cells with specific staining (indicating increased neuroendocrine cells). Neuroendocrine cell prominence appears to be related with disease severity.
Reports from current research and case series suggests that neuroendocrine cell hyperplasia of infancy may have consistent radiographic features.
Chest radiographs are non-specific but commonly show hyperinflation.
The most common features are ground glass opacification (GGO), most commonly affecting the right middle lobe and lingula, followed by a mosaic pattern of air trapping often involving multiple lobes. Other findings are less specific and include consolidation, hyperinflation, linear and reticular opacities, and bronchial wall thickening.
Treatment and prognosis
Treatment is generally supportive with no current consensus, but consists of:
- supplemental oxygen if hypoxic
- adequate nutrition
- treatment of overlapping infections
Long term prognosis of neuroendocrine cell hyperplasia of infancy is generally good with most patients improving over time, however some patients may develop persistent lung disease with airway obstruction and recurrent respiratory infections.
- 1. Caimmi S, Licari A, Caimmi D, Rispoli A, Baraldi E, Calabrese F et al. Neuroendocrine cell hyperplasia of infancy: an unusual cause of hypoxemia in children. Italian Journal of Pediatrics. 2016;42(1).
- 2. Spagnolo P, Bush A. Interstitial Lung Disease in Children Younger Than 2 Years. PEDIATRICS. 2016;137(6):e20152725-e20152725.
- 3. Young L, Brody A, Inge T, Acton J, Bokulic R, Langston C et al. Neuroendocrine Cell Distribution and Frequency Distinguish Neuroendocrine Cell Hyperplasia of Infancy From Other Pulmonary Disorders. Chest. 2011;139(5):1060-1071.
- 4. Brody A, Guillerman R, Hay T, Wagner B, Young L, Deutsch G et al. Neuroendocrine Cell Hyperplasia of Infancy: Diagnosis With High-Resolution CT. American Journal of Roentgenology. 2010;194(1):238-244.
- 5. Lukkarinen H, Pelkonen A, Lohi J, Malmstrom K, Malmberg L, Kajosaari M et al. Neuroendocrine cell hyperplasia of infancy: a prospective follow-up of nine children. Archives of Disease in Childhood. 2012;98(2):141-144.
- 6. Chejfec G, Lee I, Warren W, Gould V. Bombesin in human neuroendocrine (NE) neoplasms. Peptides. 1985;6:107-112.
- 7. Deterding R, Pye C, Fan L, Langston C. Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatric Pulmonology. 2005;40(2):157-165.